Table 10.9-3. Malaria prevention during travel depending on the risk of infection and drug resistance of Plasmodium species (WHO)

Risk of malaria in the region of destination

Recommended prophylaxis


Very low risk of Plasmodium spp infection

Mosquito bite precautions only

Very few regions in Central and East Asia and in North Africa

Risk of P vivax malaria only

Mosquito bite precautions + chemoprophylaxis (chloroquine or atovaquone/proguanil, doxycycline, or mefloquine)a

Some Caribbean islands, some regions in Central and South America and Central Asia

Risk of P falciparum malaria, plasmodium resistance to chloroquine

Mosquito bite precautions + chemoprophylaxis (atovaquone/proguanil, doxycycline, or mefloquine)a

The majority of malaria-endemic regions worldwide

Risk of P falciparum malaria + documented mefloquine resistance

Mosquito bite precautions + chemoprophylaxis (atovaquone/proguanil or doxycycline)a

Southeast Asia: some regions of Myanmar, Thailand, and Cambodia

a In regions with very low risk of P falciparum infection and documented multidrug resistance, the use of mosquito bite precautions only and SBET is permitted.

Adapted from WHO International Travel and Health 2012 (updated 2017).

SBET, standby emergency treatment; WHO, World Health Organization.